Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Sleep Medicine · Narcolepsy Type 1

Medications and Treatment Strategies

At a Glance

Narcolepsy Type 1 treatment is individualized: oxybates and pitolisant may help both daytime sleepiness and cataplexy, while other medicines mainly improve wakefulness or suppress cataplexy. Choice depends on blood pressure, mood, pregnancy plans, and medication safety.

Managing Narcolepsy Type 1 (NT1) is not about a one-size-fits-all approach. Because NT1 affects both your ability to stay awake and your muscle control, treatment is highly individualized to target your specific “dominant” symptoms—typically Excessive Daytime Sleepiness (EDS) and cataplexy [1][2].

Targeting Both EDS and Cataplexy

Some medications are “dual-action,” meaning they can improve wakefulness during the day while also reducing the frequency of cataplexy attacks.

  • Oxybate Therapy: Oxybates (sodium oxybate and low-sodium oxybate) are powerful, evidence-based options that consolidate nighttime sleep, which in turn reduces daytime sleepiness and cataplexy [3][4].
    • The Sodium Difference: Standard sodium oxybate contains a significant amount of sodium. Low-sodium oxybate provides about 92% less sodium, making it a preferred choice for reducing sodium exposure in those at risk for high blood pressure or heart disease [5][6]. However, low-sodium oxybate carries the exact same risks of respiratory depression, sedation, confusion, and misuse as standard oxybate.
    • Safety Requirements: Because oxybates are strong CNS depressants, they come with strict safety protocols (such as REMS programs in the U.S.). You must take them exactly as prescribed (some require twice-nightly divided doses, while others are once-nightly extended-release), and never combine them with alcohol or other sedatives [7][8].
  • Pitolisant: This is a newer, non-controlled medication that works by increasing histamine in the brain [9]. It is effective for EDS and has evidence supporting its use for reducing cataplexy, though its specific approval for cataplexy varies by jurisdiction [1][10]. It requires monitoring for QT prolongation (a heart rhythm issue) and drug interactions.

Medications for Wakefulness (EDS)

If sleepiness is your primary concern, your doctor may recommend wake-promoting agents. The order of preference depends on local guidelines, medication access, and your overall health.

  • Modafinil and Armodafinil: These are often used for EDS. They are generally well-tolerated but primarily target sleepiness rather than cataplexy [1][11]. Crucially, these medications can reduce the effectiveness of hormonal contraception, so alternative birth control methods must be discussed.
  • Solriamfetol: This is a potent wake-promoting agent that has shown significant improvement in daytime alertness. However, it can increase blood pressure and heart rate, so regular cardiovascular monitoring is required [12][13].
  • Traditional Stimulants: Medications like methylphenidate or amphetamines may be used if other treatments aren’t sufficient or available, though they carry a higher risk of side effects, cardiovascular impact, and potential for misuse [14][15].

Medications for Cataplexy

While oxybates and pitolisant treat cataplexy, some patients benefit from other medications.

  • Antidepressants (Off-label): Medications like venlafaxine (an SNRI) or clomipramine (a tricyclic) are frequently used “off-label” to suppress cataplexy [16][17].
  • The Rebound Risk: It is critical never to stop anticataplectic medications abruptly or without medical supervision. Doing so can cause severe rebound cataplexy, where attacks become much more frequent or severe than they were before treatment [18][19].

Customizing Your Care

Your treatment plan must account for your overall health and life stage:

  • Cardiovascular Health: If you have high blood pressure, your doctor may prioritize low-sodium options or avoid certain stimulants [20][21].
  • Psychiatric History: Since some narcolepsy medications (like stimulants, solriamfetol, and oxybates) can affect mood, your doctor will monitor you closely for symptoms of depression or anxiety [22][12].
  • Pregnancy and Contraception: Many narcolepsy medications are not recommended during pregnancy, and some (like modafinil and pitolisant) interfere with birth control. If you are planning a family, it is essential to have a preconception discussion with your sleep specialist to plan a supervised change in your medication. Never stop your medication suddenly on your own [23][24].

Common questions in this guide

Which medicines can treat both daytime sleepiness and cataplexy in narcolepsy type 1?
Oxybate medicines can improve nighttime sleep, reduce excessive daytime sleepiness, and decrease cataplexy. Pitolisant can improve wakefulness and may reduce cataplexy, although approval for cataplexy differs by country.
Is low-sodium oxybate safer than regular sodium oxybate?
Low-sodium oxybate provides about 92% less sodium and may be useful when reducing sodium exposure matters, such as with high blood pressure or heart disease. It has the same important risks as standard oxybate, including sedation, breathing problems, confusion, and misuse, and must not be combined with alcohol or other sedatives.
Can narcolepsy medications affect birth control?
Yes. Modafinil and armodafinil can reduce the effectiveness of hormonal contraception, and pitolisant can also interfere with some hormonal birth control. Discuss reliable alternative or backup contraception with your clinician before using these medicines.
What can happen if I stop a cataplexy medicine suddenly?
Stopping an anticataplectic medicine abruptly can cause rebound cataplexy, with attacks becoming more frequent or severe. Do not stop or change it without a supervised plan from your clinician.
What side effects should be monitored with narcolepsy treatment?
Solriamfetol and traditional stimulants can raise blood pressure or heart rate, while some medicines can affect mood. Oxybates can cause sedation, breathing problems, confusion, and misuse risk, so your clinician may monitor cardiovascular health, mood, and safe dosing.
What should I do if I am planning pregnancy while taking narcolepsy medication?
Tell your sleep specialist before trying to conceive; many narcolepsy medicines are not recommended during pregnancy, and some affect birth control. Your clinician can plan a supervised medication change and symptom-management strategy, so do not stop treatment suddenly on your own.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms, should we start with a medication that treats both EDS and cataplexy, or target them separately?
  2. 2.Given my cardiovascular health and blood pressure, is low-sodium oxybate a better option for me, keeping in mind the other risks remain the same?
  3. 3.If we decide to use an off-label antidepressant for my cataplexy, what are the specific side effects I should watch for?
  4. 4.How will we monitor my mood and mental health while I am taking these medications, especially if we use oxybates or solriamfetol?
  5. 5.If I am planning to become pregnant, which medications require a supervised change, and what is the plan for managing my symptoms during that time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.

    Thorpy MJ, Bogan RK

    Sleep medicine 2020; (68()):97-109 doi:10.1016/j.sleep.2019.09.001.

    PMID: 32032921
  2. 2

    Clinical pearls for the treatment of narcolepsy.

    Bulloch MN, Geyer JD

    The mental health clinician 2025; (15(6)):258-266 doi:10.9740/mhc.2025.12.258.

    PMID: 41358039
  3. 3

    Treatment paradigms for cataplexy in narcolepsy: past, present, and future.

    Swick TJ

    Nature and science of sleep 2015; (7()):159-69 doi:10.2147/NSS.S92140.

    PMID: 26715865
  4. 4

    Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

    Heo YA

    CNS drugs 2022; (36(5)):541-549 doi:10.1007/s40263-022-00912-6.

    PMID: 35357671
  5. 5

    Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.

    Junnarkar G, Allphin C, Profant J, et al.

    Expert opinion on drug discovery 2022; (17(2)):109-119 doi:10.1080/17460441.2022.1999226.

    PMID: 34818123
  6. 6

    Increased Risk of New-Onset Hypertension in Patients With Narcolepsy Initiating Sodium Oxybate: A Real-World Study.

    Ben-Joseph RH, Somers VK, Black J, et al.

    Mayo Clinic proceedings 2024; (99(11)):1710-1721 doi:10.1016/j.mayocp.2024.05.029.

    PMID: 39177543
  7. 7

    The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017.

    Strunc MJ, Black J, Lillaney P, et al.

    Drugs - real world outcomes 2021; (8(1)):15-28 doi:10.1007/s40801-020-00223-6.

    PMID: 33439474
  8. 8

    Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary.

    Dauvilliers Y, Roth T, Bogan R, et al.

    Journal of comparative effectiveness research 2024; (13(9)):e240031 doi:10.57264/cer-2024-0031.

    PMID: 39088033
  9. 9

    Pitolisant: A Review in Narcolepsy with or without Cataplexy.

    Lamb YN

    CNS drugs 2020; (34(2)):207-218 doi:10.1007/s40263-020-00703-x.

    PMID: 31997137
  10. 10

    Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.

    Szakacs Z, Dauvilliers Y, Mikhaylov V, et al.

    The Lancet. Neurology 2017; (16(3)):200-207 doi:10.1016/S1474-4422(16)30333-7.

    PMID: 28129985
  11. 11

    Pharmacological management of narcolepsy with and without cataplexy.

    Kallweit U, Bassetti CL

    Expert opinion on pharmacotherapy 2017; (18(8)):809-817 doi:10.1080/14656566.2017.1323877.

    PMID: 28443381
  12. 12

    Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.

    Zhou X, Chen J, Xu B, Chen L

    Frontiers in pharmacology 2024; (15()):1415918 doi:10.3389/fphar.2024.1415918.

    PMID: 39588154
  13. 13

    Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome: Endorsed by the French Sleep Research and Medicine Society (SFRMS) and the French Speaking Society of Respiratory Diseases (SPLF).

    Barateau L, Baillieul S, Andrejak C, et al.

    Respiratory medicine and research 2024; (86()):101105 doi:10.1016/j.resmer.2024.101105.

    PMID: 38861872
  14. 14

    Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.

    Maski K, Trotti LM, Kotagal S, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(9)):1881-1893 doi:10.5664/jcsm.9328.

    PMID: 34743789
  15. 15

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    European journal of neurology 2021; (28(9)):2815-2830 doi:10.1111/ene.14888.

    PMID: 34173695
  16. 16

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    Journal of sleep research 2021; (30(6)):e13387 doi:10.1111/jsr.13387.

    PMID: 34173288
  17. 17

    Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy.

    Parmar A, Murray BJ, Narang I

    Current neurology and neuroscience reports 2020; (20(9)):38 doi:10.1007/s11910-020-01057-z.

    PMID: 32651734
  18. 18

    Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

    Dauvilliers Y, Šonka K, Bogan RK, et al.

    CNS drugs 2022; (36(6)):633-647 doi:10.1007/s40263-022-00926-0.

    PMID: 35635687
  19. 19

    Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.

    Plazzi G, Ruoff C, Lecendreux M, et al.

    The Lancet. Child & adolescent health 2018; (2(7)):483-494 doi:10.1016/S2352-4642(18)30133-0.

    PMID: 30169321
  20. 20

    Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations.

    Kwon Y, Gami AS, Javaheri S, et al.

    Journal of the American Heart Association 2024; (13(16)):e035168 doi:10.1161/JAHA.124.035168.

    PMID: 39119988
  21. 21

    Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.

    White WB, Kovacs RJ, Alexander JK, et al.

    Hypertension (Dallas, Tex. : 1979) 2025; (82(12)):2162-2171 doi:10.1161/HYPERTENSIONAHA.125.25730.

    PMID: 41090230
  22. 22

    Narcolepsy and psychiatric comorbidity: a review of the literature.

    Verstraete L, Van Den Bossche M

    International journal of clinical and health psychology : IJCHP 2025; (25(2)):100591 doi:10.1016/j.ijchp.2025.100591.

    PMID: 40546276
  23. 23

    The association between narcolepsy during pregnancy and maternal-fetal risk factors/outcomes.

    Wilson A, Dongarwar D, Carter K, et al.

    Sleep science (Sao Paulo, Brazil) 2022; (15(3)):297-304 doi:10.5935/1984-0063.20220054.

    PMID: 36158716
  24. 24

    Type 1 Narcolepsy in Pregnancy: A Case Report and Review of Literature.

    Yuabov A, Kilinsky A, El Kady D

    AJP reports 2024; (14(2)):e120-e123 doi:10.1055/a-2297-4583.

    PMID: 38682093

This page is for informational purposes only and does not constitute medical advice about Narcolepsy Type 1 treatment. Ask your sleep specialist before starting, stopping, or changing any medication.

Get notified when new evidence is published on narcolepsy 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.